Sign in

    Sadia Rehman

    Research Analyst at Wells Fargo & Company

    Sadia Rahman is Vice President of Biopharma Equity Research at Wells Fargo, specializing in the biotechnology and pharmaceutical sectors. She focuses on covering a range of major biopharmaceutical companies, providing in-depth analysis to institutional investors, though specific companies and quantitative performance metrics are not publicly detailed. Rahman began her current role at Wells Fargo after an advanced research background, including postdoctoral work and published scientific studies in molecular biology, further strengthening her expertise in the biopharma space. She holds a senior equity research position and combines her scientific credentials with industry knowledge, supporting her role as a credible analyst in the healthcare sector.

    Sadia Rehman's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership

    Sadia Rehman's questions to BIOMARIN PHARMACEUTICAL (BMRN) leadership • Q4 2024

    Question

    Sadia Rehman, on for Mohit Bansal, asked if the upcoming DMD data would include biomarkers like splicing levels for comparison with other agents, and whether the decision to escalate to a 9 mg/kg dose was based on the 13-week data.

    Answer

    Chief R&D Officer Gregory Friberg clarified that the 9 mg/kg dose escalation was a planned step, approved by the independent Data Monitoring Committee based on safety, not a reaction to the 13-week efficacy data. He confirmed they are using multiple assays to measure dystrophin and will be transparent with the data, but did not commit to presenting other specific biomarkers like splicing levels at this time.

    Ask Fintool Equity Research AI